

# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/092,095	03/06/2002	Brian Bates	8627-051	8504
75	90 03/31/2005		EXAMINER	
J. Matthew Buchanan			WEBB, SARAH K	
BRINKS HOFER GILSON & LIONE P.O. Box 10395			ART UNIT	PAPER NUMBER
Chicago, IL 60610			3731	

DATE MAILED: 03/31/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summan	10/092,095	BATES, BRIAN				
Office Action Summary	Examiner	Art Unit				
:	Sarah K Webb	3731				
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply If NO period for reply is specified above, the maximum statutory period we Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONI	mety filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 15 Ma	<u>arch 2005</u> .					
2a) ☐ This action is FINAL. 2b) ☑ This action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is						
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims						
4) Claim(s) 1-13,15-19,21,22,24-34 and 36-39 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) 1-13,15-19,21,22,24-34 and 36-39 is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or	r election requirement.					
Application Papers						
9) The specification is objected to by the Examine	r.	·				
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the	drawing(s) be held in abeyance. Se	ee 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct						
11) The oath or declaration is objected to by the Ex	aminer. Note the attached Offic	e Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list	s have been received. s have been received in Applica rity documents have been receiv u (PCT Rule 17.2(a)).	tion No ved in this National Stage				
Attachment(s)						
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  Paper No(s)/Mail Date						
<ul> <li>2) Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)</li> <li>Paper No(s)/Mail Date</li> </ul>	_	Patent Application (PTO-152)				
C. Dahart and Tandamark Office						

Application/Control Number: 10/092,095

Art Unit: 3731

#### **DETAILED ACTION**

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 1. Claims 1-3,9-13,21,22,24, and 39 are rejected under 35 U.S.C. 102(b) as being anticipated by US Patent No. 5,951,599 to McCrory.

McCrory discloses a stent frame that has a uniform circumference and a partial graft in Figure 2A. A graft (22) is disposed over a portion of the frame (20) that extends only a portion of the length of the frame and a portion of the circumference of the frame. The graft extends approximately ½ of the circumference. McCrory states that the graft material is an impermeable polymer that is attached to the frame by various attachment means (column 4, lines 14-19). Regarding claim 10, the graft can be woven into the frame wires, and this is considered to meet the limitation "embedded."

2. Claims 1-3,8-13,21,22,24,28,29, and 39 are rejected under 35 U.S.C. 102(e) as being anticipated by US Patent App. Pub. No. 2003/0139802 (Wulfman et al.).

Wulfman discloses a stent frame that defines a uniform circumference and a plurality of cells. As shown in Figure 3, a partial graft (28) is disposed over

approximately ½ of the circumference of the frame (26) and extends the entire length of the frame. Figure 6 shows that the graft can extend only a portion of the stent length. Wulfman states that the graft material (28) is an impermeable polymer material that is attached to the frame by various attachment means (0033). Regarding claim 10, the frame can be "embedded" between inner and outer layers of the graft material [0035]. The stent-graft can be deployed by a balloon catheter [0038-0039] to occlude an aneurysm.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 3. Claims 4-7,18,19, and 30-34 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wulfman in view of US Patent No. 6,080,191 to Summers.

As explained above, Wulfman includes many limitations of the claims, but fails to form the stent frame according to claims 4-7,18,19, and 30-34. Wulfman teaches, "Stents having a variety of pore structures and shapes are well know in the art and may be adapted for use in the medical devices of the present invention" (0028]. Summers discloses several stent patterns in Figures 1-5 and 21 that meet many limitations of the claims. The embodiment of the stent in Figures 1-5 is formed from a single wire (column 3, line 65), has ring segments joined by curved regions, and adjacent rings are interleaved. The embodiment in Figure 21 has a longitudinal support. It would

Application/Control Number: 10/092,095

Art Unit: 3731

have been obvious to one of ordinary skill in the art at the time the invention was made to use a stent frame of Summers as the support frame in the Wulfman device, as this is simply an equivalent substitute for the mesh disclosed by Wulfman.

4. Claims 15-17 and 25-27 rejected under 35 U.S.C. 103(a) as being unpatentable over Wulfman in view of US Patent No. 6,464,720 to Boatman et al.

Wulfman fails to include three radiopaque markers adjacent to the edge of the graft material. The edge of the graft material is at the edge of the stent frame, so radiopaque markers at the edge of the stent frame would meet this limitation.

Boatman discloses a wire frame stent. Boatman teaches that it is particularly useful to have three radiopaque markers positioned at both the proximal and distal ends of the stent so that it can be clearly viewed to determine its exact location (column 19, lines 21-67). As shown in Figure 28, three radiopaque markers (102,103,104) are located at the edge of the stent frame. It would have been obvious to one of ordinary skill in the art at the time the invention was made to include three radiopaque markers at the edge of the Wulfman stent frame, as Boatman teaches that this arrangement of radiopaque markers aids in the determination of the exact location of the stent in the body.

### Response to Arguments

5. Applicant's arguments, see pages 7-9, filed 3/15/05, with respect to the 102 and 103 rejection(s)of the claim(s) under Avellanet, Deem, and Summers have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of McCrory and Wulfman.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarah K Webb whose telephone number is (571) 272-4706. The examiner can normally be reached on Mon-Fri 8-4:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anhtuan T. Nguyen can be reached on (571) 272-4963. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

SKW - 3/25/05

JULIAN W. WOO
PRIMARY EXAMINER

Julian W. Moo